Fermenta Biotech Ltd (BSE: 506414) is a Thane, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,399 Cr, it ranks #1,417 by market cap among the 6,137 Indian listed companies on FinBizNet, and #43 of 86 in Medicinal Chemicals and Botanical Products. At ₹450.60 (as of 25 Oct 2026), the share price is 22.7% below its 52-week high of ₹582.65 and 5.7% above its 52-week low of ₹426.30. The share price is up 35.4% over one year and up 63.1% over three months.
| Current Price | ₹450.60 |
|---|---|
| Market Cap | ₹1,399 Cr |
| BSE Code | 506414 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 18.8 |
| Return on Equity | 18.51% |
| Return on Assets | 7.74% |
| 52-Week Range | ₹426.30 – ₹582.65 |
| 1-Year Price Change | +35.4% |
| 3-Month Price Change | +63.1% |
| Beta (1Y) | -0.66 |
| Dividend Yield | 0.81% |
| Headquarters | Thane, Maharashtra |
| Website | fermentabiotech.com |
| Revenue | ₹122 Cr |
|---|---|
| Net Profit | ₹10 Cr |
| Net Margin | 7.8% |
| EPS (Basic) | ₹3.40 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Fermenta Biotech Limited, together with its subsidiaries, manufactures and markets chemicals, bulk drugs, and enzymes in India, Europe, the United States, and internationally. It provides pharmaceutical formulations and environmental solutions; rents and sells properties; and sports and health awareness/education services. The company also offers various variants of vitamin D3, including crystalline oil, resin oil, cold water dispersible, and feed grade powder for use in various applications, such as pharmaceuticals, dietary and nutritional supplements, feed, injectables, soft gel capsules, premixes, food and beverage fortification, veterinary, feed, and rodenticides; pharmaceutical ingredients comprising phenyramidol and silicon dry powder; nutritional premixes; and enzymes for use in oleochemicals, fine chemicals, active pharmaceutical ingredients, food and fragrances, leather, and biodiesel industries. In addition, it engages in the design, engineering, procurement, and construction
1. Bulk Drugs/chemicals-This segment manufactures and sells bulk drugs and enzymes. 2. Property-This segment rents properties. 3. Inter-Segment-0 4. Unallocated-0
1. Bulk Drugs/Chemicals-94% 2. Property-1.7% 3. Unallocated-4.3%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Fermenta Biotech Ltd | ₹1,399 Cr | 18.8 | 18.51% | ₹122 Cr | +35.4% |
Listed by market capitalisation. Ratios are shown for context only.
Fermenta Biotech Ltd is trading at ₹450.60, with a market capitalisation of ₹1,399 Cr.
Fermenta Biotech Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Fermenta Biotech Ltd has a P/E of 18.8 and a return on equity of 18.51%.
Fermenta Biotech Ltd is listed on the BSE under the scrip code 506414.
Fermenta Biotech Ltd's share price is up 35.4% over one year and up 63.1% over three months. Its 52-week range is ₹426.30 to ₹582.65.
In Q1 FY27, Fermenta Biotech Ltd reported revenue of ₹122 Cr and net profit of ₹10 Cr, with basic EPS of ₹3.4 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.